|
|
|
Volumn 91, Issue 2, 1998, Pages 399-405
|
|
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DENILEUKIN DIFTITOX;
HYBRID PROTEIN;
INTERLEUKIN 2 RECEPTOR;
ADOLESCENT;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER IMMUNOTHERAPY;
CANCER REGRESSION;
CHILL;
CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG TOLERABILITY;
EDEMA;
FEMALE;
FEVER;
HODGKIN DISEASE;
HUMAN;
HYPOTENSION;
IMMUNOHISTOCHEMISTRY;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MALE;
NONHODGKIN LYMPHOMA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SKIN LYMPHOMA;
T CELL LYMPHOMA;
ADOLESCENT;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
DIPHTHERIA TOXIN;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
INTERLEUKIN-2;
LIGANDS;
LYMPHOMA;
MALE;
MIDDLE AGED;
RECEPTORS, INTERLEUKIN-2;
RECOMBINANT FUSION PROTEINS;
TREATMENT OUTCOME;
|
|
EID: 17744401939
PISSN: 00064971
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (197)
|
|
References (8)
|
